Precision’s next-generation genome engineering technologies, collectively known as the Directed Nuclease Editor or DNE, aids in making the tools and resulting cells possible.
Precision chief scientific officer and co-inventor Jeff Smith said, "This newly issued patent provides the company with broad claims to many of the methods used by DNE nucleases to modify eukaryotic cells."
Precision’s DNE technology enables accurate gene editing with engineered nucleases.